Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply-Reference-Cited by-同舟云学术

Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply

Published:2024-05-13 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

van der Geest Kornelis S M¹^ORCID,Sandovici Maria¹,Rutgers Abraham¹^ORCID,Brouwer Elisabeth¹^ORCID

Affiliation:

1. Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen , Groningen, The Netherlands

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keae261/58101203/keae261.pdf

Reference8 articles.

1. Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement;Manzo;Rheumatology (Oxford)

2. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement;Vermeulen;Rheumatology (Oxford),2024

3. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative;Dasgupta;Ann Rheum Dis,2012

4. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica;van der Geest;Rheumatology (Oxford),2021

5. The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica—a prospective study of 101 patients;Nielsen;Eur J Nucl Med Mol Imaging,2024